Response assessment in <scp>W</scp>aldenstrÃ¶m ma <scp>VI</scp>th <scp>I</scp>nternational <scp>W</sc

British Journal of Haematology

160, 171-176

DOI: 10.1111/bjh.12102

Citation Report

#	Article	IF	Citations
1	WaldenstrÃ¶m macroglobulinaemia: the key questions. British Journal of Haematology, 2013, 162, 295-303.	1.2	7
2	Primary therapy of WaldenstrÃ¶m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, 122, 3276-3282.	0.6	180
3	Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 250-252.	0.2	9
4	MYD88 L265P is a marker highly characteristic of, but not restricted to, WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2013, 27, 1722-1728.	3.3	238
5	WaldenstrÃ¶m macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2013, 88, 703-711.	2.0	46
6	Challenges With Serum Protein Electrophoresis in Assessing Progression and Clinical Response in Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 247-249.	0.2	9
7	WaldenstrÃ¶m's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi155-vi159.	0.6	62
8	WaldenstrÃ¶m Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models. ISRN Hematology, 2013, 2013, 1-25.	1.6	23
9	How to manage Waldenstromâ€™s macroglobulinemia. Leukemia, 2013, 27, 762-772.	3.3	42
10	WaldenstrÃ¶m's macroglobulinemia - a review. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2014, 60, 490-499.	0.3	2
11	Current and future therapeutic approach for WaldenstrÃ¶mâ€™s macroglobulinemia. Immunotherapy, 2014, 6, 333-348.	1.0	1
12	Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology American Society of Hematology Education Program, 2014, 2014, 113-118.	0.9	34
13	Impact of Informative Censoring on the Kaplan-Meier Estimate of Progression-Free Survival in Phase II Clinical Trials. Journal of Clinical Oncology, 2014, 32, 3068-3074.	0.8	44
14	Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 768-773.	0.6	28
15	PI3KÎ´ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. New England Journal of Medicine, 2014, 370, 1008-1018.	13.9	956
16	WaldenstrÃ¶m macroglobulinemia: from biology to treatment. Expert Review of Hematology, 2014, 7, 157-168.	1.0	16
17	Guidelines on the diagnosis and management of <scp>W</scp>aldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2014, 165, 316-333.	1.2	52
18	BEAM-conditioned autologous SCT improves the quality of response in WaldenstrÃ¶mâ€™s macroglobulinaemia and lymphoplasmacytic lymphoma: a single centreâ€™s 10-year experience. Bone Marrow Transplantation, 2014, 49, 1231-1232.	1.3	7

#	Article	IF	Citations
19	Overview on clinical trials in Waldenstrom's macroglobulinemia. Clinical Investigation, 2014, 4, 1139-1154.	0.0	0
20	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	0.6	138
21	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating WaldenstrÃ¶m's macroglobulinemia. Blood, 2014, 124, 503-510.	0.6	168
22	WaldenstrÃ¶m macroglobulinemia at 70. International Journal of Hematologic Oncology, 2014, 3, 253-266.	0.7	0
23	WaldenstrÃ¶m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. Journal of Hematology and Oncology, 2015, 8, 74.	6.9	15
24	Lenalidomide is safe and active in <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2015, 90, 1055-1059.	2.0	23
25	How I treat WaldenstrÃ¶m macroglobulinemia. Blood, 2015, 126, 721-732.	0.6	165
26	WaldenstrÃ¶m macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2015, 90, 346-354.	2.0	36
27	Bendamustine and rituximab combination is safe and effective as salvage regimen in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2015, 56, 2637-2642.	0.6	55
28	Kidney Diseases Associated With Monoclonal Immunoglobulin Mâ€“Secreting B-Cell Lymphoproliferative Disorders: A Case Series of 35 Patients. American Journal of Kidney Diseases, 2015, 66, 756-767.	2.1	68
29	Multiple Myeloma. PET Clinics, 2015, 10, 227-241.	1.5	5
30	Emerging therapeutic options for WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 1143-1156.	1.1	5
31	Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2015, 56, 97-102.	0.6	12
32	Otlertuzumab (TRU â€016), an antiâ€•CD 37 monospecific ADAPTIR â„¢ therapeutic protein, for relapsed or refractory NHL patients. British Journal of Haematology, 2015, 168, 38-45.	1.2	33
33	Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer Journal, 2015, 5, e394-e394.	2.8	41
34	Phase II clinical trials for Waldenstromâ€™s macroglobulinemia. Expert Opinion on Orphan Drugs, 2015, 3, 537-547.	0.5	0
35	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia, 2015, 29, 2338-2346.	3.3	34
36	MYD88mutant lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leukemia and Lymphoma, 2015, 56, 420-425.	0.6	16

#	Article	IF	Citations
37	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016, 127, 411-419.	0.6	231
38	Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 194-205.	0.7	5
39	Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. Cancer Treatment and Research, 2016, 169, 321-361.	0.2	6
40	Histological transformation to diffuse large Bâ€cell lymphoma in patients with WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2016, 91, 1032-1035.	2.0	53
41	Renal disease related to WaldenstrÃ¶m macroglobulinaemia: incidence, pathology and clinical outcomes. British Journal of Haematology, 2016, 175, 623-630.	1.2	68
42	Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for <scp>MRD</scp> detection in multiple myeloma. Cytometry Part B - Clinical Cytometry, 2016, 90, 61-72.	0.7	177
43	Effective treatment of Bingâ€Neel Syndrome with oral fludarabine: a case series of four consecutive patients. British Journal of Haematology, 2016, 172, 461-464.	1.2	18
44	Plasma Cell Disorders. Primary Care - Clinics in Office Practice, 2016, 43, 677-691.	0.7	22
45	Efficacy and longâ€term toxicity of the rituximabâ€fludarabineâ€cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. American Journal of Hematology, 2016, 91, 782-786.	2.0	27
46	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.4	43
47	WaldenstrÃ¶m's macroglobulinemia: a clinical perspective in the era of novel therapeutics. Annals of Oncology, 2016, 27, 233-240.	0.6	13
48	TCL1 expression patterns in WaldenstrÃ¶m macroglobulinemia. Modern Pathology, 2016, 29, 83-88.	2.9	4
49	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma, 2016, 57, 1104-1113.	0.6	40
50	Treatment of patients with WaldenstrÃ¶m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2017, 47, 35-49.	0.5	10
51	WaldenstrÃ¶m macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2017, 92, 209-217.	2.0	42
52	InfiltraciÃ³n menÃngea de linfoma linfoplasmocÃtico: sÃndrome de Bing-Neel. Revista Del Laboratorio ClÃnico, 2017, 10, 49-54.	0.1	1
53	Investigation and management of IgM and WaldenstrÃ¶mâ€associated peripheral neuropathies: recommendations from the <scp>IWWM</scp>â€8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	1.2	58
54	Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. Journal of Neurology, 2017, 264, 1132-1135.	1.8	16

#	Article	IF	Citations
55	Current options to manage WaldenstrÃ¶mâ€™s macroglobulinemia. Expert Review of Hematology, 2017, 10, 637-647.	1.0	4
56	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. American Journal of Hematology, 2017, 92, 668-673.	2.0	75
58	Current treatment options and investigational drugs for Waldenstromâ€™s Macroglobulinemia. Expert Opinion on Investigational Drugs, 2017, 26, 197-205.	1.9	12
59	Lowâ€dose bortezomib and dexamethasone as primary therapy in elderly patients with WaldenstrÓ§m macroglobulinemia. European Journal of Haematology, 2017, 99, 489-494.	1.1	4
60	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	1.2	25
61	CXCL13 levels are elevated in patients with WaldenstrÃ¶m macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica, 2017, 102, e452-e455.	1.7	22
62	Transformed WaldenstrÃ¶m macroglobulinaemia: clinical presentation and outcome. A multiâ€institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (<scp>FILO</scp>). British Journal of Haematology, 2017, 179, 439-448.	1.2	39
63	Retrospective analysis of prognostic factors for WaldenstrÓ§m macroglobulinemia: a multicenter cooperative study in Japan. International Journal of Hematology, 2017, 106, 681-690.	0.7	3
64	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. Leukemia and Lymphoma, 2017, 58, 1589-1597.	0.6	2
65	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2017, 58, 1506-1508.	0.6	9
66	Idelalisib in WaldenstrÃ¶m macroglobulinemia: high incidence of hepatotoxicity. Leukemia and Lymphoma, 2017, 58, 1002-1004.	0.6	31
67	WaldenstrÃ¶m Macroglobulinaemia: Pathological Features and Diagnostic Assessment. , 2017, , 3-19.		0
68	Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. , 2017, , 239-261.		0
69	Response Assessment in WaldenstrÃ¶mâ€™s Macroglobulinaemia. , 2017, , 265-275.		0
70	WaldenstrÃ¶mâ€™s Macroglobulinemia Immunophenotype. , 2017, , 21-34.		3
71	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404.	3.2	23
72	Disease control should be the goal of therapy for WM patients. Blood Advances, 2017, 1, 2483-2485.	2.5	5
73	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2017, 35, 3898-3905.	0.8	320

#	Article	IF	Citations
74	Immunophenotyping of Mature B-Cell Lymphomas. , 0, , 105-127.		1
75	Response and survival for primary therapy combination regimens and maintenance rituximab in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 181, 77-85.	1.2	41
76	Bendamustine plus rituximab for indolent Bâ€cell lymphoma of renal significance. American Journal of Hematology, 2018, 93, 356-362.	2.0	6
77	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	0.8	71
78	How we manage patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 181, 737-751.	1.2	8
79	WaldenstrÃ¶mâ€™s Macroglobulinemia. Hematologic Malignancies, 2018, , 191-220.	0.2	2
80	Ibrutinib discontinuation in WaldenstrÃ¶m macroglobulinemia: Etiologies, outcomes, and IgM rebound. American Journal of Hematology, 2018, 93, 511-517.	2.0	61
81	Phase 1 study of the PI3KÎ´ inhibitor INCB040093 Â± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood, 2018, 132, 293-306.	0.6	45
82	Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Leukemia and Lymphoma, 2018, 59, 259-261.	0.6	10
83	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leukemia and Lymphoma, 2018, 59, 1554-1564.	0.6	43
84	First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival. Blood, 2018, 131, 368-371.	0.6	30
85	A global call to arms for clinical laboratories â€“ Harmonised quantification and reporting of monoclonal proteins. Clinical Biochemistry, 2018, 51, 4-9.	0.8	19
86	Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761.	0.8	142
87	WaldenstrÃ¶mâ€™s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv41-iv50.	0.6	63
88	Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Research, 2018, 53, 189.	0.5	10
89	Onsets of progression and second treatment determine survival of patients with symptomatic WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2018, 2, 3102-3111.	2.5	3
90	Impact of ibrutinib dose intensity on patient outcomes in previously treated WaldenstrÃ¶m macroglobulinemia. Haematologica, 2018, 103, e466-e468.	1.7	18
91	WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0

#	Article	IF	Citations
92	Flow Cytometry. Hematology/Oncology Clinics of North America, 2018, 32, 765-775.	0.9	20
93	Waldenstromâ€™s Macroglobulinemia. , 2018, , 617-638.		0
94	Idelalisib in a patient with refractory WaldenstrÃ¶mâ€™s macroglobulinemia complicated by anuric renal failure: a case report. Journal of Medical Case Reports, 2018, 12, 164.	0.4	2
95	A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with WaldenstrÃ¶m macroglobulinemia. Future Oncology, 2018, 14, 2229-2237.	1.1	37
96	Kidney Involvement of Patients with WaldenstrÃ¶m Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1037-1046.	2.2	46
97	Ibrutinib for Treating WaldenstrÃ¶mâ€™s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 7-18.	1.7	1
98	CXCR4 mutation subtypes impact response and survival outcomes in patients with WaldenstrÃ¶m macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2019, 187, 356-363.	1.2	73
99	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 639-656.	0.9	12
101	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2019, 25, 4907-4916.	3.2	36
102	Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis . OncoTargets and Therapy, 2019, Volume 12, 2751-2766.	1.0	9
103	Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders. Kidney International, 2019, 96, 94-103.	2.6	16
104	Phase I study of tirabrutinib (ONOâ€4059/GSâ€4059) in patients with relapsed or refractory Bâ€cell malignancies in Japan. Cancer Science, 2019, 110, 1686-1694.	1.7	43
105	Parsaclisib, a potent and highly selective PI3KÎ´ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood, 2019, 133, 1742-1752.	0.6	84
106	Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2019, 60, 964-970.	0.6	11
107	Diagnostic framing of IgM monoclonal gammopathy: Focus on WaldenstrÃ¶m macroglobulinemia. Hematological Oncology, 2019, 37, 117-128.	0.8	15
108	Long survival in patients with WaldenstrÃ¶m macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802.	1.2	4
109	Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with WaldenstrÃ¶m macroglobulinaemia on ibrutinib. British Journal of Haematology, 2019, 185, 788-790.	1.2	12
110	WaldenstrÃ¶m macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2019, 94, 266-276.	2.0	68

#	Article	IF	Citations
111	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 2019, 133, 299-305.	0.6	69
112	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 1011-1014.	1.2	19
113	Deepening of response after completing rituximabâ€containing therapy in patients with Waldenstrom macroglobulinemia. American Journal of Hematology, 2020, 95, 372-378.	2.0	6
114	Acalabrutinib monotherapy in patients with WaldenstrÃ¶m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematology,the, 2020, 7, e112-e121.	2.2	119
115	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	3.3	40
116	A practical guide to laboratory investigations at diagnosis and follow up in WaldenstrÃ¶m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178.	0.3	23
117	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With WaldenstrÃ¶m Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363.	1.2	12
118	Zanubrutinib for the treatment of patients with WaldenstrÃ¶m macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	0.6	78
119	A multicenter, openâ€label, phase II study of tirabrutinib (ONO/GSâ€4059) in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. Cancer Science, 2020, 111, 3327-3337.	1.7	60
120	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WaldenstrÃ¶m macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	0.6	281
121	Complete Response of a Young Woman With MYD88WT Bing-Neel Syndrome on Ibrutinib Monotherapy Following a Single Cycle of B Hyper-CVAD/IT MTX. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e809-e812.	0.2	0
122	Younger patients with WaldenstrÃ¶m Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. American Journal of Hematology, 2020, 95, 1473-1478.	2.0	7
123	Systemic Amyloidosis due to Low-Grade Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 1027-1039.	0.9	8
124	A rare case of MGRS with immunotactoid glomerulopathy responding to bortezomib, dexamethasone, and rituximab. Clinical Case Reports (discontinued), 2020, 8, 1984-1987.	0.2	2
125	Zanubrutinib for the treatment of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	2.5	57
126	Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. International Journal of Cancer, 2020, 147, 1979-1986.	2.3	6
127	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	0.8	103
128	High plasma D-dimer level is a poor prognostic factor for patients with waldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1140-1146.	0.6	1

#	Article	IF	Citations
129	Waldenstrom's macroglobulinemia in the era of immunotherapy. Leukemia and Lymphoma, 2020, 61, 1292-1304.	0.6	1
130	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	0.6	9
131	WaldenstrÃ¶m Macroglobulinemia: Clinico-pathological Profile and Treatment Outcomes of Patients from a Tertiary Care Centre of North India. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 386-390.	0.3	0
132	Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
133	Current and Emerging Treatments for WaldenstrÃ¶m Macroglobulinemia. Acta Haematologica, 2021, 144, 146-157.	0.7	7
134	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	0.8	98
135	Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. OncoImmunology, 2021, 10, 1936392.	2.1	14
136	Clinical application of genomics in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	0.6	3
137	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology, 2021, 96, 846-853.	2.0	16
138	Clinicopathological features of Chinese patients with Bâ€cell lymphoproliferative disorders and kidney infiltration. Nephrology, 2021, 26, 650-658.	0.7	1
139	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for WaldenstrÃ¶m macroglobulinemia. Neoplasia, 2021, 23, 361-374.	2.3	16
140	Phase I, first-in-human trial of Brutonâ€™s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	1
141	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. Scientific Reports, 2021, 11, 10069.	1.6	3
142	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2021, 5, 2438-2446.	2.5	20
143	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 678-689.	5.1	83
144	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
145	Retrospective Analysis of the Impact of Adverse Eventâ€“Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e432-e448.	0.2	11
146	WaldenstrÃ¶m macroglobulinemia and relationship to immune deficiency. Leukemia and Lymphoma, 2021, 62, 2665-2670.	0.6	1

#	Article	IF	Citations
147	Chemokine Receptor 4â€“Targeted 68Ga-Pentixafor PET/CT in Response Assessment of WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma. Clinical Nuclear Medicine, 2021, 46, 732-737.	0.7	9
148	Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	1.7	11
149	The Spectrum of Ocular Manifestations in Patients with WaldenstrÃ¶mâ€™s Macroglobulinemia. Ocular Immunology and Inflammation, 2021, , 1-10.	1.0	5
150	Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e886-e894.	0.2	8
151	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2021, 27, 5492-5501.	3.2	19
152	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory WaldenstrÃ¶m's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. Journal of Clinical Oncology, 2022, 40, 40-51.	0.8	22
153	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539.	3.3	50
154	WaldenstrÃ¶m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2021, 96, 258-269.	2.0	49
155	Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 757-757.	0.6	6
156	KIDNEY DISEASE ASSOCIATED WITH MONOCLONAL GAMMOPATHIES: SINGLE-CENTER STUDY. Nephrology (Saint-Petersburg), 2018, 22, 38-46.	0.1	8
157	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for WaldenstrÃ¶m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology, 2022, 40, 52-62.	0.8	62
158	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2014, , 303-329.		0
159	WaldenstrÃ¶m Macroglobulinemia: Clinical Presentation, Diagnosis, and Management. Journal of the Advanced Practitioner in Oncology, 2020, 11, 381-389.	0.2	2
160	WaldenstrÃ¶m Macroglobulinemia: A Clinicopathological Profile and Review of Six Cases. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 596-601.	0.1	0
161	Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. EJNMMI Research, 2021, 11, 110.	1.1	3
162	Clinical and morphological spectrum and long-term outcome in monoclonal gammopathy of renal signiï¬cance: one center study. Nephrology (Saint-Petersburg), 2020, 24, 19-27.	0.1	1
163	Paraprotein Sample Exchange in Australia and New Zealand - 2018. Clinical Biochemist Reviews, 2019, 40, 43-54.	3.3	3
164	The Paraprotein - an Enduring Biomarker. Clinical Biochemist Reviews, 2019, 40, 5-22.	3.3	16

#	Article	IF	Citations
165	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2020, 4, 5089-5092.	2.5	5
166	Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2022, 40, 63-71.	0.8	53
167	Postâ€•relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological Oncology, 2022, 40, 49-57.	0.8	2
168	Plamotamab (XmAb^{Â®}13676) for Ibrutinib- refractory CXCR4-mutated extramedullary WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2022, 63, 738-742.	0.6	2
169	A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2022, 63, 1058-1069.	0.6	3
170	Diagnosis and management of WaldenstrÃ¶m macroglobulinaemiaâ€”A British Society for Haematology guideline. British Journal of Haematology, 2022, 197, 171-187.	1.2	30
171	A Case of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib. Internal Medicine, 2022, , .	0.3	0
172	Response and survival predictors in a cohort of 319 patients with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	2.5	12
173	Mast cell density and its clinical relevance in WaldenstrÃ¶m's macroglobulinemia. EJHaem, 2022, 3, 371-378.	0.4	1
174	Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 1728-1732.	0.6	2
175	A twoâ€•part, singleâ€•arm, multicentre, phase I study of zanubrutinib, a selective <scp>Bruton tyrosine kinase</scp> inhibitor, in Chinese patients with relapsed/refractory Bâ€•cell malignancies. British Journal of Haematology, 2022, 198, 62-72.	1.2	10
176	Firstâ€•versus secondâ€•generation Bruton tyrosine kinase inhibitors in WaldenstrÃ¶m's Macroglobulinemia: A systematic review and metaâ€•analysis. American Journal of Hematology, 2022, 97, 942-950.	2.0	5
177	Twoâ€•year outcomes of tirabrutinib monotherapy in WaldenstrÃ¶mâ€™s macroglobulinemia. Cancer Science, 2022, 113, 2085-2096.	1.7	15
181	Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy. Journal of Neurology, 2022, 269, 4955-4960.	1.8	4
182	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney International, 2022, 102, 382-394.	2.6	6
183	Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual. Journal of Clinical Oncology, 2022, 40, 2600-2608.	0.8	3
184	A pilot study on dasatinib in patients with WaldenstrÃ¶m macroglobulinemia progressing on ibrutinib. EJHaem, 2022, 3, 927-929.	0.4	1
185	Differential Diagnosis of WaldenstrÃ¶mâ€™s Macroglobulinemia and Early Management: Perspectives from Clinical Practice. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 107-117.	1.2	5

#	Article	IF	Citations
186	Baseline 18F-FDG PET/CT May Portend the Prognosis of Patients With WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment. Clinical Nuclear Medicine, 2022, 47, 954-960.	0.7	2
187	Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Global Oncology, 2022, , .	0.8	3
188	The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. Cancers, 2022, 14, 3814.	1.7	10
189	Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. Frontiers in Immunology, 0, 13, .	2.2	2
190	Successful and safe response to ibrutinib alone in treating relapsed WaldenstrÃ¶m macrogobulinemia and related acquired von Willebrand syndrome: an option to consider. Leukemia and Lymphoma, 0, , 1-5.	0.6	0
191	Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory WaldenstrÃ¶m's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine, 2022, 52, 101682.	3.2	15
192	Molecular remission is an independent predictor of progressionâ€free survival in patients with WaldenstrÃ¶m macroglobulinemia treated with chemoâ€immunotherapy: Results from the FIL_BIOWM study. Hematological Oncology, 2023, 41, 574-577.	0.8	1
193	Clinicopathologic characteristics and prognostic analysis of monoclonal gammopathy of renal significance (MGRS) in patients with IgM monoclonal gammopathy: a case series. Scientific Reports, 2022, 12, .	1.6	1
194	IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis. Hemato, 2022, 3, 731-741.	0.2	0
195	Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematology,the, 2023, 10, e35-e45.	2.2	22
196	A phase 1, open-label, randomized drugâ€“drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leukemia and Lymphoma, 2023, 64, 329-338.	0.6	1
197	Light chain amyloidosis associated with WaldenstrÃ¶m macroglobulinemia: treatment and survival outcomes. Haematologica, 2023, 108, 1680-1684.	1.7	2
198	Dose reductions in patients with WaldenstrÃ¶m macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2023, 201, 897-904.	1.2	10
199	Zanubrutinib in patients with treatmentâ€naÃ¯ve or relapsed/refractory WaldenstrÃ¶m macroglobulinemia: An expandedâ€access study of 50 patients in the United States. EJHaem, 2023, 4, 301-304.	0.4	2
200	Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies. International Journal of Hematology, 2023, 117, 553-562.	0.7	5
201	Ibrutinib in relapsed/refractory patients with WaldenstrÃ¶m macroglobulinemia: a real-life, retrospective study on behalf of the â€œRTLâ€•(regional Tuscan lymphoma network). Annals of Hematology, 0, , .	0.8	1
202	Lymphoplasmacytic lymphoma with IgG-Îº paraproteinemia presenting as a hepatic bulky mass. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, 62, 273-278.	0.3	0
203	Unique Presentation of Bingâ€“Neel Syndrome With Co-existing Chronic Lymphocytic Leukemia. HemaSphere, 2022, 6, e805.	1.2	0

#	Article	IF	Citations
204	Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for WaldenstrÃ¶m's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for WaldenstrÃ¶m's Macroglobulinemia. Journal of Clinical Oncology, 2023, 41, 2607-2616.	0.8	16
205	Bendamustine plus rituximab for the treatment of WaldenstrÃ¶m Macroglobulinemia: Patient outcomes and impact of bendamustine dosing. American Journal of Hematology, 2023, 98, 750-759.	2.0	3
206	BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstromâ€™s Macroglobulinemia. Journal of Clinical Medicine, 2023, 12, 2378.	1.0	0
207	Report of Consensus Panel 6 from the 11 th International Workshop on WaldenstrÃ¶m's Macroglobulinemia on Management of WaldenstrÃ¶m's Macroglobulinemia Related Amyloidosis. Seminars in Hematology, 2023, , .	1.8	0
208	Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Seminars in Hematology, 2023, 60, 97-106.	1.8	7
224	Waldenstrom Macroglobulinemia. , 2024, , .		0